Incyte Corporation

Incyte Corporation (INCY) is the lead sponsor of 57 active clinical trials listed on ClinicalTrials.gov^[4], including 20 Phase 3^[1], 18 Phase 2^[2], 19 Phase 1^[3].

Trial NCT06855498^[5] evaluates povorcitinib in Hidradenitis Suppurativa (HS) with a target enrollment of 600 participants. Trial NCT04824092^[6] evaluates Tafasitamab in Diffuse Large B-cell Lymphoma with a target enrollment of 899 participants. Trial NCT06804811^[7] evaluates Ruxolitinib Cream in NonSegmental Vitiligo with a target enrollment of 250 participants.

INCY has 5 Form 4 insider filings recorded at the SEC in the past 30 days^[8].